newsfilter
← Latest News
PR Newswire·

Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates

FPI-2265 (Ac-PSMA I&T) IND transferred to Fusion; program is enrolling patients and on track for Q1 2024 update Preliminary clinical data presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI)